Trial
NCT00867126
Pioglitazone as Second-Line in Patients With Metastatic Pancreatic Cancer After Treatment With Gemcitabine
Early Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
University of Texas Southwestern Medical Center
Collaborators
—
Condition
Pancreatic Cancer
Intervention
pioglitazone hydrochloride
Why stopped
low accrual
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2018-11-26